The case for SBRT as kidney cancer treatment

In this video interview, Dr Vitaly Margulis, from the University of Texas Southwestern Medical Center in Dallas, outlines the advantages of stereotactic body radiation therapy (SBRT) and talks about the forthcoming RADVAX clinical trial in the USA, which combines radiotherapy and immunotherapy. Oncologists are often taught that renal cell carcinoma (RCC) is resistant to radiotherapy. […]

read more

Stereotactic radiation for the treatment of kidney cancer

This paper reviews the use of stereotactic body radiotherapy (SBRT) for the treatment of renal cell carcinoma (RCC), and was presented at the Society of Urologic Oncology (SUO) in Washington last week. In conclusion: RCC is radiosensitive and SBRT can be used to stabilise or manage the symptoms of primary tumours SBRT may be useful […]

read more

SBRT in combination with systemic treatment for metastatic kidney cancer

Two recent studies have looked at the effect of stereotactic body radiotherapy (SBRT) in combination with tyrosine kinase inhibitors or immune checkpoint inhibitors on renal cell carcinoma (RCC) metastases and survival. In the first study, a total of 17 patients with stable metastatic RCC were assessed. The effect of SBRT on the target metastasis was […]

read more

Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology¬†this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]

read more
Showing all 4 results
  TOP